Navigation Links
Interim Safety Data Favorable for Vical's Phase 2 Trial of DNA Vaccine Against CMV
Date:10/17/2007

SAN DIEGO, Oct. 17 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced that an independent data safety monitoring board (DSMB) found no safety issues and recommended continuation of the company's Phase 2 trial of a DNA vaccine against cytomegalovirus (CMV). The DSMB completed an interim evaluation of safety data after the two-month follow-up visits for the first 20 hematopoietic stem cell transplant (HCT) recipients enrolled in the study.

Because most HCT recipients are expected to face a natural viral challenge as pre-existing CMV infection reactivates under immunosuppression, the primary efficacy endpoint in the double-blind, placebo-controlled Phase 2 trial is the occurrence rate of clinically significant CMV levels in HCT patients receiving vaccine compared with patients receiving placebo. Other important endpoints include immune responses against the specific CMV features targeted by the vaccine. The trial also is comparing safety of the vaccine against placebo in up to 80 matched, related HCT donors and recipients, and up to 80 additional HCT recipients. The DSMB evaluated safety data only in the interim analysis.

About CMV

CMV is a herpes virus that infects more than half of all adults in the United States by age 40, and is even more widespread in developing countries. While a healthy immune system typically protects an infected person against CMV disease, it rarely succeeds in completely eliminating the infection, and those whose immune systems are not fully functional are at high risk of CMV proliferation, potentially leading to severe illness or death. These include transplant patients who take immunosuppressive drugs, and fetuses and newborns of mothers who first become infected during pregnancy.

CMV infection affects 30 to 60 percent of the patients undergoing various transplant procedures, causing transplant rejection, serious illness and even death if untreated. Expensive antiviral drug therapy is used to control the disease, but does not eliminate the infection. Congenital CMV infection affects one out of every hundred infants, and causes severe consequences in about 3,600 infants and death in about 400 each year in the United States.

There is no approved vaccine against CMV. Vaccine approaches that result in predominantly antibody responses to CMV have not proven highly effective in transplant patients. Vaccine approaches using live, attenuated viruses can induce both antibody and cellular immune responses, but pose a potential safety concern, particularly for immunocompromised patients, of causing the disease they are intended to prevent. Vical's novel DNA vaccine approach is designed to induce both antibody and cellular immune responses against specific features of the CMV virus without the risk of causing CMV disease. Vical's vaccine has received orphan drug designation for hematopoietic stem cell transplant and solid organ transplant patients.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected, including: whether the company will successfully enroll 80 matched, related stem cell transplant donor/recipient pairs or 80 additional recipients in a timely manner, if at all; whether the CMV vaccine will achieve the safety and efficacy endpoints in the Phase 2 trial for stem cell transplant donors and/or recipients, including whether the favorable interim safety data are predictive of safety data for the full trial; whether the company will expand development of a CMV vaccine to address prevention of congenital disease; whether the vaccine will induce both antibody and cellular immune responses; whether the vaccine will prevent clinically significant CMV levels; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contacts: Investors: Media:

Alan R. Engbring Susan Neath

Vical Incorporated Porter Novelli Life Sciences

(858) 646-1127 (619) 849-6007

Website: http://www.vical.com


'/>"/>
SOURCE Vical Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 23, 2017  The particle counters market is ... from USD 275.9 million in 2016, at a ... report: http://www.reportlinker.com/p04718602-summary/view-report.html The growing ... R&D, and growth in manufacturing industries in emerging ... for particle counters. On the other hand, technical ...
(Date:2/24/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The latest research Urinary Incontinence Drugs Price Analysis ... the global Urinary Incontinence market. The research answers the following ... marketed for Urinary Incontinence and their clinical attributes? How are they ...
(Date:2/23/2017)... YORK , Feb. 23, 2017  Genesis Healthcare ... Company. The announcement was made by Bill Monast ... David Hartley and Nathan Feltman , executives ... Genesis Healthcare Services, LLC. This acquisition ... largest provider of technology enabled durable medical equipment (DME) ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the ... studies, the Center for Disease Control ( CDC ) and Infectious Diseases Society of ... Liegner, M.D. has compiled into a single volume a compelling argument that the disease ...
(Date:2/27/2017)... ... February 27, 2017 , ... Sunshine Coast ... in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the ... Mackenzie Alsager, showcases the Centre's commitment to innovation in drug rehab and alcohol ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair Institute, ... announce an upgrade to the company's Yelp listing. Bay Area residents struggling from ... diverse as Platelet Rich Plasma (PRP) therapy, hair transplantation techniques such as Follicular ...
(Date:2/26/2017)... MICHIGAN (PRWEB) , ... February 25, 2017 , ... The ... Kim Jong-un, heightened awareness and concern over nerve agents and the deadly use of ... the human nervous system and how even small doses can be lethal. , Jay ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... lab became the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der ... , ISO/IEC 17025:2005 is the globally recognised standard that sets out requirements for ...
Breaking Medicine News(10 mins):